{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:16:59Z","timestamp":1783401419613,"version":"3.54.6"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Academy of Consultation-Liaison Psychiatry"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jaclp.2026.03.006","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T20:59:09Z","timestamp":1774040349000},"page":"202-212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic Dysfunction-Associated Steatotic Liver Disease in Schizophrenia: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"67","author":[{"given":"Marcel","family":"Camino-i-Gibernau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego A.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7444-9634","authenticated-orcid":false,"given":"Ramiro","family":"Manzano-Nunez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaclp.2026.03.006_bib1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/wps.20420","article-title":"Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls","volume":"16","author":"Correll","year":"2017","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jaclp.2026.03.006_bib2","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1192\/j.eurpsy.2020.115","article-title":"Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: a Delphi expert consensus study","volume":"64","author":"Galderisi","year":"2021","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.jaclp.2026.03.006_bib3","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/schbul\/sbr148","article-title":"Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis","volume":"39","author":"Mitchell","year":"2013","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jaclp.2026.03.006_bib4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/jamapsychiatry.2016.3803","article-title":"Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis","volume":"74","author":"Pillinger","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jaclp.2026.03.006_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41398-023-02716-8","article-title":"Glucose dysregulation in antipsychotic-naive first-episode psychosis: in silico exploration of gene expression signatures","volume":"14","author":"Lee","year":"2024","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.jaclp.2026.03.006_bib6","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jaclp.2026.03.006_bib7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms","volume":"125","author":"Reynolds","year":"2010","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jaclp.2026.03.006_bib8","article-title":"Clinical and molecular implications of antipsychotics in MASLD","author":"Gonzalez","year":"2025","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jaclp.2026.03.006_bib9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1192\/bjp.bp.110.084665","article-title":"Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation","volume":"199","author":"De Hert","year":"2011","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jaclp.2026.03.006_bib10","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jaclp.2026.03.006_bib11","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2337\/dci24-0094","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American diabetes association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jaclp.2026.03.006_bib12","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1007\/s00213-016-4422-7","article-title":"Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study","volume":"233","author":"Morl\u00e1n-Coarasa","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jaclp.2026.03.006_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.1042442","article-title":"Non-alcoholic fatty liver disease (NAFLD) and mental illness: mechanisms linking mood, metabolism and medicines","volume":"16","author":"Gangopadhyay","year":"2022","journal-title":"Front Neurosci"},{"key":"10.1016\/j.jaclp.2026.03.006_bib14","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jaclp.2026.03.006_bib15","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-Analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jaclp.2026.03.006_bib16","series-title":"JBI Manual for Evidence Synthesis","author":"Aromataris","year":"2024"},{"key":"10.1016\/j.jaclp.2026.03.006_bib17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12874-017-0468-4","article-title":"What kind of systematic review should I conduct? A proposed typology and guidance for systematic reviewers in the medical and health sciences","volume":"18","author":"Munn","year":"2018","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jaclp.2026.03.006_bib18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","article-title":"Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data","volume":"13","author":"Munn","year":"2015","journal-title":"Int J Evid Based Healthc"},{"key":"10.1016\/j.jaclp.2026.03.006_bib19","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jhep.2024.01.014","article-title":"Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease","volume":"80","author":"Younossi","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jaclp.2026.03.006_bib20","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.jhep.2023.07.021","article-title":"Can we use old NAFLD data under the new MASLD definition?","volume":"80","author":"Song","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jaclp.2026.03.006_bib21","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1111\/liv.15695","article-title":"Exploring the landscape of steatotic liver disease in the general US population","volume":"43","author":"Ciardullo","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jaclp.2026.03.006_bib22","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/wps.20252","article-title":"Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis","volume":"14","author":"Vancampfort","year":"2015","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jaclp.2026.03.006_bib23","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.jaclp.2026.03.006_bib24","doi-asserted-by":"crossref","first-page":"467","DOI":"10.11124\/JBIES-22-00224","article-title":"Assessing the risk of bias of quantitative analytical studies: introducing the vision for critical appraisal within JBI systematic reviews","volume":"21","author":"Munn","year":"2023","journal-title":"JBI Evid Synth"},{"key":"10.1016\/j.jaclp.2026.03.006_bib25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a Stata command to perform meta-analysis of binomial data","volume":"72","author":"Nyaga","year":"2014","journal-title":"Arch Public Health"},{"key":"10.1016\/j.jaclp.2026.03.006_bib26","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jaclp.2026.03.006_bib27","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1080\/08039488.2021.1939779","article-title":"Hepatic steatosis in patients with schizophrenia: a clinical cross-sectional study","volume":"76","author":"Aar\u00f8e","year":"2022","journal-title":"Nord J Psychiatry"},{"key":"10.1016\/j.jaclp.2026.03.006_bib28","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/JCP.0000000000001421","article-title":"Risk of nonalcoholic fatty liver disease in patients with schizophrenia treated with antipsychotic drugs: a cross-sectional study: a cross-sectional study","volume":"41","author":"Koreki","year":"2021","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jaclp.2026.03.006_bib29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s12072-020-10132-z","article-title":"Prevalence of nonalcoholic fatty liver disease in mental disorder inpatients in China: an observational study","volume":"15","author":"Ma","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jaclp.2026.03.006_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpsychores.2025.112192","article-title":"Clinical and inflammatory markers associated with metabolic dysfunction-associated fatty liver disease in a cohort of individuals with chronic schizophrenia (FACE-SZ)","volume":"195","author":"Tokarski","year":"2025","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.jaclp.2026.03.006_bib31","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2147\/NDT.S398385","article-title":"Prevalence and influence factors for non-alcoholic fatty liver disease in long-term hospitalized patients with schizophrenia: a cross-sectional retrospective study","volume":"19","author":"Li","year":"2023","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.jaclp.2026.03.006_bib32","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2147\/NDT.S137183","article-title":"The prevalence and risk factors of young male schizophrenics with non-alcoholic fatty liver disease","volume":"13","author":"Yan","year":"2017","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.jaclp.2026.03.006_bib33","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2147\/DMSO.S437811","article-title":"Prevalence and risk factors of non-alcoholic fatty liver disease (NAFLD) in non-obese patients with schizophrenia: a retrospective study","volume":"17","author":"Yi","year":"2024","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.jaclp.2026.03.006_bib34","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/00912174241280510","article-title":"Psychotropic medication and hepatobiliary health: ultrasound observations on patients with schizophrenia","volume":"60","author":"Yue","year":"2025","journal-title":"Int J Psychiatry Med"},{"key":"10.1016\/j.jaclp.2026.03.006_bib35","first-page":"947","article-title":"Prevalence rate and risk factor analysis of nonalcoholic fatty liver disease in 115 female patients with schizophrenia","volume":"31","author":"Yu","year":"2023","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"10.1016\/j.jaclp.2026.03.006_bib36","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/jrsm.1547","article-title":"Meta-analysis of prevalence: I2 statistic and how to deal with heterogeneity","volume":"13","author":"Migliavaca","year":"2022","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.jaclp.2026.03.006_bib37","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/j.2051-5545.2011.tb00036.x","article-title":"Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level","volume":"10","author":"De Hert","year":"2011","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jaclp.2026.03.006_bib38","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jaclp.2026.03.006_bib39","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S2215-0366(24)00314-6","article-title":"Prevalence, correlates, tolerability-related outcomes, and efficacy-related outcomes of antipsychotic polypharmacy: a systematic review and meta-analysis","volume":"11","author":"H\u00f8jlund","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jaclp.2026.03.006_bib40","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/hup.2257","article-title":"Metabolic syndrome in psychiatrically hospitalized patients treated with antipsychotics and other psychotropics: metabolic syndrome in inpatients","volume":"27","author":"Centorrino","year":"2012","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.jaclp.2026.03.006_bib41","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00213-008-1370-x","article-title":"Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver","volume":"203","author":"Fern\u00f8","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jaclp.2026.03.006_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111803","article-title":"Olanzapine leads to nonalcoholic fatty liver disease through the apolipoprotein A5 pathway","volume":"141","author":"Li","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jaclp.2026.03.006_bib43","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/gutjnl-2025-336127","article-title":"Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts","volume":"75","author":"Huo","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.jaclp.2026.03.006_bib44","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1111\/jgh.15156","article-title":"Global epidemiology of lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"35","author":"Lu","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jaclp.2026.03.006_bib45","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12874-021-01381-z","article-title":"Conducting proportional meta-analysis in different types of systematic reviews: a guide for synthesisers of evidence","volume":"21","author":"Barker","year":"2021","journal-title":"BMC Med Res Methodol"}],"container-title":["Journal of the Academy of Consultation-Liaison Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667296026000406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667296026000406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:46:31Z","timestamp":1783399591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667296026000406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2667296026000406"],"URL":"https:\/\/doi.org\/10.1016\/j.jaclp.2026.03.006","relation":{},"ISSN":["2667-2960"],"issn-type":[{"value":"2667-2960","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic Dysfunction-Associated Steatotic Liver Disease in Schizophrenia: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Academy of Consultation-Liaison Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaclp.2026.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Academy of Consultation-Liaison Psychiatry. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}